Back to top

Analyst Blog

Exactech (EXAC - Snapshot Report), which develops and markets orthopedic implant devices, recently expanded its spine franchise with the launch of the Proliant polyaxial pedicle screw system for orthopedic and neurosurgeons.

The Proliant polyaxial pedicle screw system represents the first internally-developed spinal system by Exactech. It has been geared to provide secure fixation of the thoracolumbar spine and offer surgeons a simple, faster and easy-to-use posterior lumbar fixation system.

The Proliant system features a secure interlocking mechanism that stabilizes the construct. The pedicle screw’s dual lead thread design allows insertion of the screw twice as fast as standard screws, thereby saving time in the operating room.

Exactech established its spine business through a couple of acquisitions. The company added spinal fusion products (including two pedicle screw fixation systems for lumbar fusion) through its acquisition of spinal implant devices maker Altiva Corporation in January 2008.

Moreover, Exactech, in August 2010, acquired multiple spinal product lines from VertiFlex Inc, which develops less intrusive spinal surgery technologies that help preserve motion.

The launch of the Proliant system represents an important milestone for Exactech’s spine franchise as posterior lumbar fixation is a core segment of the growing spine surgery market. A full commercial launch of the product is expected in second-half 2011. 

Gainesville-based Exactech develops and markets orthopedic implant devices. Its orthopedic products are utilized in the restoration of bones as well as joints that have degenerated due to disease.

Exactech competes with the likes of  Wright Medical Group (WMGI - Analyst Report), Stryker Corp. (SYK - Analyst Report), Johnson & Johnson (JNJ - Analyst Report), and Zimmer Holdings Inc. (ZMH - Analyst Report), some of whom are much larger in size with deep R&D pockets.

Exactech recently reported better-than-expected first-quarter fiscal 2011 results. Revenues for the quarter rose 9% year over year to $53.4 million, ahead of the Zacks Consensus Estimate of $52 million. Its adjusted earnings per share of 28 cents beat the Zacks Consensus Estimate by a penny while exceeded 26 cents in the year-ago quarter.

The company registered strong growth across its hip and extremity product lines in the quarter with revenues zooming 21% and 33%, respectively. However, its biologic-spine sales fell 5%. Exactech backed its revenues and earnings guidance for fiscal 2011.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%